Respiratory dysfunction and pulmonary disease in cirrhosis and other hepatic disorders

Respiratory Care

Volumn 52, Issue 8, 2007, Pages 1030-1036

  Huffmyer, Julie L ^a   Nemergut, Edward C ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Cirrhosis; Hepatic hydrothorax; Hepatopulmonary syndrome; Liver disease; Portopulmonary hypertension

Indexed keywords

ALMITRINE DIMESILATE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOPHOSPHAMIDE; DIURETIC AGENT; INDOMETACIN; PROSTACYCLIN; SILDENAFIL; SOMATOSTATIN DERIVATIVE;

ATELECTASIS; CLINICAL FEATURE; CONTINUOUS INFUSION; DIARRHEA; FLUSHING; HEADACHE; HEPATOPULMONARY SYNDROME; HUMAN; HYDROTHORAX; HYPOXEMIA; JAW DISEASE; JAW PAIN; LEG PAIN; LIVER CIRRHOSIS; LIVER DISEASE; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; LUNG BLOOD VESSEL; LUNG DISEASE; LUNG FUNCTION; NAUSEA AND VOMITING; OXYGEN THERAPY; PATHOGENESIS; PLASMAPHERESIS; PORTOPULMONARY HYPERTENSION; PULMONARY HYPERTENSION; RESPIRATORY FAILURE; RESPIRATORY SYSTEM; REVIEW; SIDE EFFECT; THROMBOSIS; TREATMENT CONTRAINDICATION; VASODILATATION; PATHOPHYSIOLOGY; UNITED STATES;

HEPATOPULMONARY SYNDROME; HUMANS; LIVER CIRRHOSIS; UNITED STATES;

EID: 35148881307     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Anderson RN, Smith BL. Deaths: leading causes for 2002. Natl Vital Stat Rep 2005;53(17):1-89.
2. Karsan HA, Rojter SE, Saab S. Primary prevention of cirrhosis: public health strategies that can make a difference. Postgrad Med 2004;115(1):25-30.
3. Gaskari SA, Honar H, Lee SS. Therapy insight: cirrhotic cardiomyopathy. Nat Clin Pract Gastroenterol Hepatol 2006;3(6):329-337.
4. Krowka MJ. Hepatopulmonary syndromes. Gut 2000;46(1):1-4.
5. Kinasewitz GT, Keddissi JI. Hepatic hydrothorax. Curr Opin Pulm Med 2003;9(4):261-265.
6. Lazaridis KN, Frank JW, Krowka MJ, Kamath PS. Hepatic hydrothorax: pathogenesis, diagnosis, and management. Am J Med 1999;107(3):262-267.
7. Krowka MJ, Dickson ER, Cortese DA. Hepatopulmonary syndrome: clinical observations and lack of therapeutic response to somatostatin analogue. Chest 1993;104(2):515-521.
8. Ramsay MA. Portopulmonary hypertension and hepatopulmonary syndrome, and liver transplantation. Int Anesthesiol Clin 2006;44(3):69-82.
9. Berthelot P, Walker JG, Sherlock S, Reid L. Arterial changes in the lungs in cirrhosis of the liver: lung spider nevi. N Engl J Med 1966;274(6):291-298.
10. Rolla G. Hepatopulmonary syndrome: role of nitric oxide and clinical aspects. Dig Liver Dis 2004;36(5):303-308.
11. Rolla G, Brussino L, Colagrande P, Dutto L, Polizzi S, Scappaticci E, et al. Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis. Hepatology 1997;26(4):842-847.
12. Fallon MB, Abrams GA, Luo B, Hou Z, Dai J, Ku DD. The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome. Gastroenterology 1997;113(2):606-614.
13. Nunes H, Lebrec D, Mazmanian M, Capron F, Heller J, Tazi KA, et al. Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med 2001;164(5):879-885.
14. Schenk P, Madl C, Rezaie-Majd S, Lehr S, Müller C. Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med 2000;133(9):701-706.
15. Sztrymf B, Rabiller A, Nunes H, Savale L, Lebrec D, Le Pape A, et al. Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats. Eur Respir J 2004;23(5):752-758.
16. Rodriguez-Roisin R, Roca J, Agusti AG, Mastai R, Wagner PD, Bosch J. Gas exchange and pulmonary vascular reactivity in patients with liver cirrhosis. Am Rev Respir Dis 1987;135(5):1085-1092.
17. Krowka MJ, Cortese DA. Hepatopulmonary syndrome. Chest 1990;98(5):1053-1054.
18. Krowka MJ, Cortese DA. Hepatopulmonary syndrome: an evolving perspective in the era of liver transplantation. Hepatology 1990;11(1):138-142.
19. Lange PA, Stoller JK. The hepatopulmonary syndrome. Ann Intern Med 1995;122(7):521-529.
20. Rodriguez-Roisin R, Agusti AG, Roca J. The hepatopulmonary syndrome: new name, old complexities. Thorax 1992;47(11):897-902.
21. Wolfe JD, Tashkin DP, Holly FE, Brachman MB, Genovesi MG. Hypoxemia of cirrhosis: detection of abnormal small pulmonary vascular channels by a quantitative radionuclide method. Am J Med 1977;63(5):746-754.
22. Fallon MB, Abrams GA. Pulmonary dysfunction in chronic liver disease. Hepatology 2000;32(4 Pt 1):859-865.
23. Rodríguez-Roisin R, Krowka MJ, Hervé P, Fallon MB; ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 2004;24(5):861-880.
24. Yilmaz S, Dursum M, Canoruc F, Bayan K, Karabulut A, Akay H. A severe (type II) hepatopulmonary syndrome in a patient with idiopathic portal hypertension and treatment with paroxetine. Neth J Med 2005;63(11):448-452.
25. Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: impact of liver transplantation. Hepatology 2005;41(5):1122-1129.
26. Rodriguez-Roisin R, Krowka MJ. Is severe arterial hypoxaemia due to hepatic disease an indication for liver transplantation? A new therapeutic approach. Eur Respir J 1994;7(5):839-842.
27. Castro M, Krowka MJ, Schroeder DR, Beck KC, Plevak DJ, Rettke SR, et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc 1996;71(6):543-551.
28. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004;363(9419):1461-1468.
29. Kawut SM, Taichman DB, Ahya VN, Kaplan S, Archer-Chicko CL, Kimmel SE, Palevsky HI. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transplantation 2005;11(9):1107-1111.
30. Mandell MS, Groves BM. Pulmonary hypertension in chronic liver disease. Clin Chest Med 1996;17(1):17-33.
31. Panos RJ, Baker SK. Mediators, cytokines, and growth factors in liver-lung interactions. Clin Chest Med 1996;17(1):151-169.
32. Egermayer P, Town GI, Peacock AJ. Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension. Thorax 1999;54(2):161-168.
33. Edwards BS, Weir EK, Edwards WD, Ludwig J, Dykoski RK, Edwards JE. Coexistent pulmonary and portal hypertension: morphologic and clinical features. J Am Coll Cardiol 1987;10(6):1233-1238.
34. Mal H, Burgiere O, Durand F, Fartoukh M, Cohen-Solal A, Fournier M. Pulmonary hypertension following hepatopulmonary syndrome in a patient with cirrhosis. J Hepatol 1999;31(2):360-364.
35. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67(3):737-744.
36. Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangi-ectasia. N Engl J Med 2001;345(5):325-334.
37. Kuo PC, Plotkin JS, Johnson LB, Howell CD, Laurin JM, Bartlett ST, Rubin LJ. Distinctive clinical features of portopulmonary hypertension. Chest 1997;112(4):980-986.
38. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999; 30(3):641-648.
39. Makisalo H, Koivusalo A, Vakkuri A, Hockerstedt K. Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation. Liver Transpl 2004;10(7):945-950.
40. Krowka MJ. Pulmonary hypertension, (high) risk of orthotopic liver transplantation, and some lessons from "primary" pulmonary hypertension (editorial). Liver Transpl 2002;8(4):389-390.
41. Ramsay MA. Perioperative mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000;6(4):451-452.
42. Schroeder RA, Rafii AA, Plotkin JS, Johnson LB, Rustgi VK, Kuo PC. Use of aerosolized inhaled epoprostenol in the treatment of portopulmonary hypertension. Transplantation 2000;70(3):548-550.